Literature DB >> 15542063

The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.

Zheng Fu1, Eliah Aronoff-Spencer, Haiyan Wu, Gary J Gerfen, Jonathan M Backer.   

Abstract

Class IA PI 3-kinases are heterodimeric proteins with distinct catalytic (p110) and regulatory (p85) subunits. The minimal fragment of p85 capable of regulating p110 activity (p85ni) is the N-terminal SH2 domain linked to the iSH2 coiled-coil domain. We used cysteine mutagenesis and (14)C-NEM-labeling to show that the p110-binding site in the iSH2 domain includes two regions: residues 482-484 and 532-541. These regions are adjacent to each other in the three-dimensional structural model of the iSH2 domain, and define a coherent binding site. We then used spin labeling and EPR spectroscopy to demonstrate that the conformation of the iSH2 domain is unaffected by binding to the N-terminal fragment of p110 (residues 1-108), and/or by phosphopeptide binding to p85ni/p110(1-108) heterodimers. Finally, we show that the cSH2 domain cannot substitute for the nSH2 domain with regard to inhibition of p110. These data support a model in which the iSH2 domain is a rigid tether for p110, and regulation of p85/p110 is mediated by nSH2-p110 contacts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542063      PMCID: PMC3889214          DOI: 10.1016/j.abb.2004.09.032

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  20 in total

1.  Alternative modes of binding of proteins with tandem SH2 domains.

Authors:  R O'Brien; P Rugman; D Renzoni; M Layton; R Handa; K Hilyard; M D Waterfield; P C Driscoll; J E Ladbury
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

2.  The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Jonathan M Backer; Gary J Gerfen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit.

Authors:  Tung O Chan; Ulrich Rodeck; Andrew M Chan; Alec C Kimmelman; Susan E Rittenhouse; George Panayotou; Philip N Tsichlis
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

4.  Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits.

Authors:  K H Holt; L Olson; W S Moye-Rowley; J E Pessin
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

Review 5.  Synthesis and function of 3-phosphorylated inositol lipids.

Authors:  B Vanhaesebroeck; S J Leevers; K Ahmadi; J Timms; R Katso; P C Driscoll; R Woscholski; P J Parker; M D Waterfield
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

6.  Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.

Authors:  D A Fruman; F Mauvais-Jarvis; D A Pollard; C M Yballe; D Brazil; R T Bronson; C R Kahn; L C Cantley
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site.

Authors:  T Weber; B Schaffhausen; Y Liu; U L Günther
Journal:  Biochemistry       Date:  2000-12-26       Impact factor: 3.162

8.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

Authors:  A J Philp; I G Campbell; C Leet; E Vincan; S P Rockman; R H Whitehead; R J Thomas; W A Phillips
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85.

Authors:  P Hu; A Mondino; E Y Skolnik; J Schlessinger
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation.

Authors:  S E Shoelson; M Sivaraja; K P Williams; P Hu; J Schlessinger; M A Weiss
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more
  11 in total

1.  PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein.

Authors:  Zhenqi Zhu; Xin He; Carla Johnson; John Stoops; Amanda E Eaker; David S Stoffer; Aaron Bell; Reza Zarnegar; Marie C DeFrances
Journal:  Biochem Biophys Res Commun       Date:  2007-04-24       Impact factor: 3.575

2.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

3.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Authors:  Haiyan Wu; S Chandra Shekar; Rory J Flinn; Mirvat El-Sibai; Bijay S Jaiswal; K Ilker Sen; Vasantharajan Janakiraman; Somasekar Seshagiri; Gary J Gerfen; Mark E Girvin; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

Review 4.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

Review 5.  Structural effects of oncogenic PI3Kα mutations.

Authors:  Sandra B Gabelli; Chuan-Hsiang Huang; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 6.  The regulation of class IA PI 3-kinases by inter-subunit interactions.

Authors:  Jonathan M Backer
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K).

Authors:  Yoshihiro Ito; Jonathan R Hart; Lynn Ueno; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

8.  PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation.

Authors:  Ekaterina Bobrovnikova-Marjon; Dariusz Pytel; Matthew J Riese; Laura Pontano Vaites; Nickpreet Singh; Gary A Koretzky; Eric S Witze; J Alan Diehl
Journal:  Mol Cell Biol       Date:  2012-04-09       Impact factor: 4.272

9.  Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Authors:  Minghao Sun; Petra Hillmann; Bianca T Hofmann; Jonathan R Hart; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

10.  The structure of p85ni in class IA phosphoinositide 3-kinase exhibits interdomain disorder.

Authors:  K Ilker Sen; Haiyan Wu; Jonathan M Backer; Gary J Gerfen
Journal:  Biochemistry       Date:  2010-03-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.